UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...
Hosted on MSN15d
Roche's 2024 Sales and Earnings Beat, Key Drugs Perform WellSwiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for 2025. Sales in 2024 totaled $68.7 billion, which beat the Zacks Consensus ...
It operates through the following segments: Diagnostics and Pharmaceuticals ... Read More on RHHVF: Roche NewsMORE Related Stocks Indices Commodities ...
It operates through the following segments: Diagnostics and Pharmaceuticals ... Read More on RHHVF: Roche NewsMORE Related Stocks Indices Commodities ...
Diagnostics may not be as profitable as Pharmaceuticals ... Concluding Thoughts: Is Roche Stock A “Best Buy” Within Big Pharma In 2025? As a Roche shareholder myself, am I looking forward ...
With the introduction of HER2-low and now HER2-ultralow classifications, Roche continues to lead in HER2 diagnostics, helping to expand patient access to personalised treatment. Basel, 31 January ...
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics ...
If you ever had cancer or were tested for it, there’s a good chance Roche Tissue Diagnostics played a role behind the scenes. The Tucson-area company has emerged as a global leader in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback